Orthofix Medical Inc.
No enriched coverage for $OFIX in the last 7 days.
Juniper Investment Company, LLC sold 310,000 indirectly-held shares of Orthofix Medical Inc. (OFIX) at an average of $8.81 ($8.74–$8.86, $2.73M total) across 2 trades over 2026-09-18 to 2026-09-21. Filed jointly with Bartholdson John A. (10% owner) and MICHAS ALEXIS P (10% owner).
Juniper Investment Company, LLC sold 39,500 indirectly-held shares of Orthofix Medical Inc. (OFIX) at an average of $10.20 ($10.01–$10.38, $0.40M total) across 2 trades over 2026-08-14 to 2026-08-17. Filed jointly with Bartholdson John A. (10% owner) and MICHAS ALEXIS P (10% owner).
Orthofix (OFIX) reported Q2 2026 pro forma constant-currency net sales growth of 5% year over year, with double-digit growth in Global Limb Reconstruction and Spine Fixation. Biologics net sales were about flat after prior declines. Therapeutic Solutions grew 3% despite Medicare reimbursement pressure, but CMS restored reimbursement for bone growth stimulators. Orthofix plans a Q4 launch of its VIRATA spinal implant system.
Recent OFIX coverage spans insider activity, earnings and market movers.
In the last 30 days, OFIX insiders filed 3 SEC Form 4 transactions — no purchases and 3 sales ($2.7M). The most active reporter was Juniper Investment Company, LLC with 2 filings. 33% of those filings were made under pre-arranged Rule 10b5-1 plans.
Large insider sale by a 10% owner may signal reduced confidence, potentially pressuring the stock.
This is an insider sale by a 10% owner with no 10b5-1 plan stated, which can modestly affect sentiment but is not a fundamental update.
Reimbursement restoration and product/commercial execution updates should support second-half demand visibility, but distributor and Biologics consistency remain key risks.
Guidance math and distributor-driven core growth expectations are likely to drive near-term positioning around 2H 2026 earnings power.
The article frames a reimbursement reversal as reversing OFIX’s prior revenue guidance cut, implying downside may be partially unwound.
AlphAI scores every news story that mentions OFIX with an AI model for sentiment and relevance, and aggregates insider trades from Orthofix Medical Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Juniper Investment Company, LLC sold 310,000 indirectly-held shares of Orthofix Medical Inc. (OFIX) at an average of $8.81 ($8.74–$8.86, $2.73M total) across 2 trades over 2026-09-18 to 2026-09-21. Filed jointly with Bartholdson John A. (10% owner) and MICHAS ALEXIS P (10% owner).
1 min readJuniper Investment Company, LLC sold 39,500 indirectly-held shares of Orthofix Medical Inc. (OFIX) at an average of $10.20 ($10.01–$10.38, $0.40M total) across 2 trades over 2026-08-14 to 2026-08-17. Filed jointly with Bartholdson John A. (10% owner) and MICHAS ALEXIS P (10% owner).
2 min readOrthofix (OFIX) reported Q2 2026 pro forma constant-currency net sales growth of 5% year over year, with double-digit growth in Global Limb Reconstruction and Spine Fixation. Biologics net sales were about flat after prior declines. Therapeutic Solutions grew 3% despite Medicare reimbursement pressure, but CMS restored reimbursement for bone growth stimulators. Orthofix plans a Q4 launch of its VIRATA spinal implant system.
6 min readOrthofix Medical Inc. reported Q2 2026 earnings call updates, emphasizing a shift toward distributor quality and asset utilization. Management expects 2026 net sales and EBITDA guidance to rise by $7 million, citing $12 million Medicare reimbursement restoration and $15 million European distributor benefit, partly offset by weaker smaller spine distributors. Medicare bone stimulator reimbursement was restored retroactive to May 18, 2026.
7 min readRewey Asset Management’s Q2 2026 “RAM Smid Composite” letter said the composite rose 20.06% in Q2 and 31.15% YTD. It highlighted Orthofix Medical Inc. (NASDAQ:OFIX), noting CMS reversed a May 21 reimbursement code change on July 1. OFIX closed at $11.02 on July 22, with a $441.8M market cap.
4 min readThe Russell 2000 stayed near 3,000 with little movement, while seven small-cap stocks gained at least 28% in four sessions. The article cites July surges for Orthofix (OFIX) on CMS reimbursement reversal, REGENXBIO (RGNX) on FDA resubmission alignment and AbbVie milestone, Verastem (VSTM) on short-squeeze setup, ADC Therapeutics (ADCT) rebound, Sable Offshore (SOC) refinancing, Rapid7 (RPD) takeover speculation, and Crinetics (CRNX) surge toward an offer price.
7 min readBiotech gainers: Innovative Eyewear (LUCY) rose 63% after preliminary Q2 2026 net sales of ~$0.99M (+71% YoY) and new retail orders; Seer (SEER) jumped 35% on an unsolicited $2.45/share cash takeover proposal plus contingent value rights; Orthofix (OFIX) and Enovis (ENOV) gained 16%/15% after CMS withdrew reimbursement changes for non-invasive bone growth stimulators.
6 min readOrthofix Medical shares rose 15.3% after the company said CMS reversed earlier Medicare billing/fee-schedule changes for non-invasive bone growth stimulators, restoring reimbursement to prior levels. CMS issued revised guidance July 1, 2026, withdrawing modifications tied to HCPCS codes. The stock moved from near $8.85 toward $11.46; insiders sold about $2.7M over three months.
4 min readOrthofix Medical Inc. (OFIX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K 0000884624 false 0000884624 2026-06-11 2026-06-11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11,
2 min readJuniper Investment Company, LLC sold 242,000 indirectly-held shares of Orthofix Medical Inc. (OFIX) at $10.70 ($2.59M total) on 2026-05-22.
2 min read
